Anti-CD79a antibody [JCB117 + HM47A9]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

CD79a also known as Ig-alpha or MB-1 is a component of the B cell antigen receptor (BCR) complex. It is a transmembrane protein with a molecular mass of approximately 47 kDa. CD79a is part of a heterodimer with CD79b and is mainly expressed on the surface of B lymphocytes. This protein plays a critical mechanical role in signaling transduction through the BCR by associating with membrane-bound immunoglobulin molecules helping to initiate the immune response upon antigen binding.

Biological function summary

This protein acts as an essential mediator in the immune system. CD79a together with CD79b forms part of the BCR complex critical for B cell development and maturation. The BCR complex activates signaling cascades that influence B cell fate decisions such as proliferation differentiation and apoptosis. By transmitting signals from the BCR CD79a helps regulate these cellular functions necessary for efficient immune defense.

Pathways

CD79a plays a pivotal role in the B cell receptor signaling pathway. This pathway involves signaling molecules such as spleen tyrosine kinase (SYK) and phosphoinositide 3-kinase (PI3K) which are activated upon BCR engagement. CD79a acts in concert with other proteins including CD79b and the IgM receptor facilitating downstream signaling cascades that ensure proper B cell responses. Its role is important for linking extracellular antigen recognition to intracellular signaling events.

Associated diseases and disorders

CD79a is significant in conditions like B cell lymphomas and certain immunodeficiencies. Abnormal expression or mutations in CD79a are associated with some types of non-Hodgkin lymphoma. The protein's interaction with CD79b is particularly relevant as alterations in these proteins' function or expression can impact B cell development and lead to pathogenesis in lymphoproliferative disorders. Consequently CD79a serves as an important biomarker and potential therapeutic target in these diseases.